Impact of anti-CD38 therapy in multiple myeloma with high-risk cytogenetics: systematic review and meta-analysis.

MLA

Mohyuddin, Ghulam Rehman, et al. “Impact of Anti-CD38 Therapy in Multiple Myeloma with High-Risk Cytogenetics: Systematic Review and Meta-Analysis.” Leukemia & Lymphoma, vol. 61, no. 10, Oct. 2020, pp. 2519–22. EBSCOhost, https://doi.org/10.1080/10428194.2020.1772475.

APA

Mohyuddin, G. R., Sigle, M., Chandrasekar, V. T., Aziz, M., Abdallah, A.-O., Shune, L., & McClune, B. (2020). Impact of anti-CD38 therapy in multiple myeloma with high-risk cytogenetics: systematic review and meta-analysis. Leukemia & Lymphoma, 61(10), 2519–2522. https://doi.org/10.1080/10428194.2020.1772475

Chicago

Mohyuddin, Ghulam Rehman, Monia Sigle, Viveksandeep Thoguluva Chandrasekar, Muhammad Aziz, Al-Ola Abdallah, Leyla Shune, and Brian McClune. 2020. “Impact of Anti-CD38 Therapy in Multiple Myeloma with High-Risk Cytogenetics: Systematic Review and Meta-Analysis.” Leukemia & Lymphoma 61 (10): 2519–22. doi:10.1080/10428194.2020.1772475.